Search results
Showing 1551 to 1600 of 1968 results for news
Agenda and papers of the NICE public board meeting on 19 March 2025
Agenda and papers of the NICE public board meeting on 22 March 2023
Agenda and papers of the NICE public board meeting on 20 March 2024
NICE AI-based guidance and advice . Subscribe to NICE news for life sciences Our NICE news for life sciences newsletter...
The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
Biographies and registered interests for members of the Technology Appraisal Committee C
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Day-to-day decision making is the responsibility of NICE's executive team.
A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Centre for Health Technology Evaluation Develops guidance on the use of new and existing treatments within the NHS, such as medicines,...
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
balanced and independent as possible. A new sample of members of the public are invited to take part in each new topic....
Agenda and papers of the NICE public board meeting on 18 September 2025
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
Home News Podcasts Treating type 2 diabetes with SGLT-2 inhibitors Podcasts 25 August 2025 Listen About this episode In this episode, we...
International collaboration with NICE
Home News Podcasts Innovation in action: Inside NICE's HTA Lab Podcasts 30 July 2025 Listen About this episode Our Health Technology...
Partner with NICE in our research work
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
IMI and H2020 Grant funded projects with NICE
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
Patients to receive medicines 3 to 6 months faster under 10-Year Health Plan
NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.
informed Sign up to one of our monthly newsletters. Along with our latest news, features and guidance, you'll also receive our latest...
The guidance development timeline
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,
Science policy projects with NICE.
NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Hundreds with rare inherited eye disease to benefit after NICE recommends treatment
NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.
NICE approves first immunotherapy combination for endometrial cancer
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
social care Sign up for 'NICE news for health and social care' our free monthly e-bulletin. It includes links to relevant...
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.